Loading company…
Waltham-based biopharmaceutical company developing oral integrin therapies for chronic diseases such as inflammatory bowel disease.
Morphic Holding, Inc. develops oral integrin therapies for chronic diseases such as inflammatory bowel disease, with product candidates aimed at significant unmet medical needs. Founded in 2014 and headquartered in Waltham, Massachusetts, the company raised USD 3,200.00 mn in a TRADE SALE, primarily from Eli Lilly and Company, and has completed five deals, most recently on March 2, 2021. Its founder is Timothy Springer, and it reported revenue of USD 70.81 mn and EBITDA of USD -61.59 mn for 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in